Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE Geyer, C. E., Huang, C., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Fischer, H. H., Redondo, A., Jackisch, C., Jacot, W., Conlin, A. K., Schneeweiss, A., Wapnir, I. L., Fasching, P. A., DiGiovanna, M. P., Wuelfing, P., Arce-Salinas, C., Crown, J. P., Shao, Z., Caremoli, E., Wu, H., Lam, L. H., Tesarowski, D., Smitt, M., Douthwaite, H., Singel, S. M., von Minckwitz, G. AMER ASSOC CANCER RESEARCH. 2019
View details for DOI 10.1158/1538-7445.SABCS18-GS1-10
View details for Web of Science ID 000478677000052